Shan Wu
Corporate Officer/Principal bei VIRIDIAN THERAPEUTICS, INC.
Aktive Positionen von Shan Wu
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Corporate Officer/Principal | 30.10.2023 | - |
Karriereverlauf von Shan Wu
Ehemalige bekannte Positionen von Shan Wu
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| MAGENTA THERAPEUTICS | Investor Relations Kontakt | 01.10.2021 | 01.09.2023 |
| Corporate Officer/Principal | 01.10.2021 | 01.09.2023 |
Ausbildung von Shan Wu
| Massachusetts Institute of Technology | Doctorate Degree |
| University of Virginia | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
Operativ
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Finance | 2 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |